Epidemiologist Erin Bowles, MPH, is looking at breast cancer screening and treatment from many different perspectives. Her research brings new insight into cancer risk factors, diagnosis, treatment, and survivorship, while helping improve cancer care for patients and families.
Erin received an R50 mid-career research award from the National Cancer Institute (NCI). This award is given to cancer researchers who have demonstrated successes and contributions to cancer research as a non-principal investigator. As a key member of 2 large cancer collaborations — the NCI's Breast Cancer Surveillance Consortium and the Kaiser Permanente Breast Cancer Survivors Cohort — Erin has developed diverse expertise that includes reading mammograms for breast density and using administrative data to understand patterns of breast cancer screening and cancer treatment.
Her current work includes:
Erin’s experience working with large observational cohorts and collaborations with numerous study teams over the past 20+ years has provided her with expertise in data collection and quality control for many subject areas. She is also Director of the Collaborative Science Division at KPWHRI, providing leadership, supervision, mentorship, and support to collaborative scientists with a range of skills and expertise. She is passionate about providing long-term career paths for masters- and PhD-level scientists who don’t want to become independent investigators.
Breast cancer; colorectal cancer; multiple myeloma; thyroid cancer; pancreatic cancer; biostatistics; epidemiology; mammography; mammographic breast density; cancer treatment; cancer screening and surveillance; automated data collection; quality of care; medication use; care coordination; administrative data
Access to care; health disparities; health outcomes research; quality of life; measurement of change in health care systems; practice variation
Menopause; hormone replacement therapy (HRT); breast cancer
Cognitive health and dementia; biostatistics; epidemiology; medication use; cancer
Pharmacoepidemiology; observational study research methods; chemotherapy; radiation exposure
Boudreau DM, Chen L, Yu O, Bowles EJA, Chubak J Risk of second breast cancer events with chronic opioid use in breast cancer survivors 2019 May;28(5):740-753. doi: 10.1002/pds.4779. Epub 2019-04-03. PubMed
Bowles EJA, Yu O, Ziebell R, Chen L, Boudreau DM, Ritzwoller DP, Hubbard RA, Boggs JM, Burnett-Hartman AN, Sterrett A, Fujii M, Chubak J Cardiovascular medication use and risks of colon cancer recurrences and additional cancer events: a cohort study 2019 Mar 27;19(1):270. doi: 10.1186/s12885-019-5493-8. Epub 2019-03-27. PubMed
Chubak J, Yu O, Ziebell RA, Bowles EJA, Sterrett AT, Fujii MM, Boggs JM, Burnett-Hartman AN, Boudreau DM, Chen L, Floyd JS, Ritzwoller DP, Hubbard RA Risk of colon cancer recurrence in relation to diabetes 2018 Nov;29(11):1093-1103. doi: 10.1007/s10552-018-1083-3. Epub 2018-09-22. PubMed
Lin JS, Bowles EJA, Williams SB, Morrison CC Screening for Thyroid Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force 2017 May 9;317(18):1888-1903. doi: 10.1001/jama.2017.0562. PubMed
Lin JS, Aiello Bowles EJ, Williams SB, Morrison CC Screening for Thyroid Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force 2017 May PubMed
Bowles EJA, Walker RL, Anderson ML, Dublin S, Crane PK, Larson EB Risk of Alzheimer's disease or dementia following a cancer diagnosis 2017 Jan;12(6):e0179857. doi: 10.1371/journal.pone.0179857. Epub 2017-06-20. PubMed
New research finds that 10% of pediatric blood and bone marrow cancers may have stemmed from radiation exposure.
New study will develop risk models to improve clinical guidelines and practice.
Kaiser Permanente Washington has been part of the national Breast Cancer Surveillance Consortium since 1994. Learn about the Kaiser Permanente Washington Breast Cancer Surveillance Registry here.
The division contributes to research across the institute with methodological and subject matter expertise.
MedPage Today, March 4, 2025
How KPWHRI is contributing to better cancer screening and better outcomes for patients.